Welcome to the e-CCO Library!

P583: Outcome of treat to target strategy in paediatric patients with Crohn’s disease and ulcerative colitis on adalimumab
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. Yerlioglu*1, L. Cococcioni1, A. ElZein1, S. Chadokufa1, R. Buckingham1, S. Sider1, N. Shah1, A. Ocholi1, O. Borrelli1, F. Kiparissi1

Created: Friday, 22 February 2019, 9:41 AM
P583: Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn’s disease: results from a large Italian cohort study
Year: 2021
Source: ECCO'21 Virtual
Authors: Mocci, G.(1);Cuomo, A.(2);Allegretta, L.(3);Aragona, G.(4);Colucci, R.(5);Della Valle, N.(6);Ferronato, A.(7);Forti, G.(8);Gaiani, F.(9);Graziani, M.G.(10);Lorenzetti, R.(11);Luzza, F.(12);Penna, A.(13);Pica, R.(14);Piergallini, S.(15);Rodinò, S.(16);Scarcelli, A.(17);Zampaletta, C.(18);Cicerone, C.(19);Cocco, A.(20);De Angelis, G.(9);Donnarumma, L.(2);Pranzo, G.(21);Franceschi, M.(7);Gallina, S.(18);Grasso, G.(3);Larussa, T.(12);Luppino, I.(22);Faggiani, R.(23);Fanigliulo, L.(24);Pagnini, C.(10);Perazzo, P.(4);Sacco, R.(6);Sebkova, L.(16);Serio, M.E.(25);De Monti, A.(26);Picchio, M.(27);Elisei, W.(28);Maconi, G.(26);Tursi, A.(29);
Created: Wednesday, 2 June 2021, 4:12 PM
P583: Tofacitinib for acute severe ulcerative colitis: a systematic review
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ovesen, P.D.(1)*;Brynskov, J.(1);Seidelin, J.B.(1);Steenholt, C.(1);
Created: Friday, 14 July 2023, 11:05 AM
P583: Trends in endoscopy management after surgery in a national cohort of Spanish Crohn's disease patients. Results from PRACTICROHN study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Barreiro-de Acosta M.*1, Iborra M.2, García V.3, Gutiérrez A.4, Garcia S.5, Domènech E.6, Martín Arranz M.D.7, Cea-Calvo L.8, Romero C.8, Juliá B.8

Created: Wednesday, 20 February 2019, 10:36 AM
P583: Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicenter cohort study
Year: 2022
Source: ECCO'22
Authors: Avni Biron, I.(1);Mishael, T.(2);Zittan, E.(3);Livne, M.(4);Zinger, A.(5);Tzadok, R.(6); Goldenberg, R.(7);kopylov, U.(4);Ron, Y.(6);Hadar, E.(8);Helman, S.(2);Ollech, J.(1);Farkash, R.(7);Pauker, M.(1);Yanai, H.(1);Dotan, I.(1);Bar-Gil Shitrit , A.(7);
Created: Friday, 11 February 2022, 3:56 PM
P584 Use of mycophenolate mofetil in inflammatory bowel disease: results from the ENEIDA registry
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Hernandez Camba1, L. Arranz1, I. Vera2, D. Carpio3, M. Calafat Sard4, A. Lucendo5, C. Taxonera6, S. Marín7, M.J. Garcia8, G. Suris Marín9, E. Sánchez Rodríguez10, A.Y. Carbajo11, M.L. De Castro12, M. Iborra13, A. Martin-Cardona14, I. Rodríguez Lago15, D. Busquets16, F. Bertoletti17, M. Sierra Ausín18, C. Tardillo1, J. Huguet Malaves19, L. Bujanda20, A. Castaño21, O. Merino22, E. Domènch23, L. Ramos24, ENEIDA Project of GETECCU

Created: Thursday, 30 January 2020, 10:12 AM
P584: A role for therapeutic drug-monitoring during infliximab induction treatment in inflammatory bowel disease?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Rasmussen M.*1, Brynskov J.1, Ainsworth M.A.1, Buhl S.1, Bendtzen K.2, Steenholdt C.1

Created: Wednesday, 20 February 2019, 10:36 AM
P584: Combining faecal calprotectin and sigmoidoscopy can predict mucosal healing in paediatric ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Park1, Y. Kang1, H. Koh1, S. Kim*1

Created: Friday, 22 February 2019, 9:41 AM
P584: Efficacy, safety, and tolerability of AMT-101, a gut selective oral IL-10 fusion, in the Phase 2 FILLMORE trial of patients with chronic pouchitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Jairath, V.(1)*;Bressler , B.(2);Silverberg , M.S.(3);Lee, L.Y.(4);Lugo, K.A.(4);Mayoral Monibas, R.(4);Annamalai, T.(4);Whitney, J.A.(4);Weng, E.Y.(4);Kanwar, B.(4);Danese , S.(5);Feagan, B.(1);
Created: Friday, 14 July 2023, 11:05 AM
P584: Mucosal Eosinophilia is an Independent Predictor of Vedolizumab Effectiveness in Ulcerative Colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Gremida, A.(1);Huang, K.(1);Ciorba, M.(1);Deyali , C.(1);Deepak, P.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P584: Rare and severe complications in children with paediatric-onset IBD; the international PIBD SETQuality Safety Registry by PIBDnet
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Aardoom1*, P. Kemos2, F. Ruemmele3, N. Croft2, L. de Ridder1, on behalf of the PIBD SETQuality consortium and PIBDnet

Created: Thursday, 21 February 2019, 9:14 AM
P584: Systematic Review and Meta-analysis Evaluating the Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease
Year: 2022
Source: ECCO'22
Authors: Hosack, T.(1);Gadhok, R.(2);Lindsay, J.O.(2);
Created: Friday, 11 February 2022, 3:56 PM
P585 Evaluation and comparison of the safety profiles of different intravenous iron preparations and oral iron for treatment of iron deficiency anaemia: Preliminary results from the IBD subgroup analysis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Aksan1,2,3, H. Işık4, S. Aksan2, D. Tuğal5, A. Dignass6, J.M. Stein2,3,7

Created: Thursday, 30 January 2020, 10:12 AM
P585: Duration of response to ozanimod after treatment withdrawal: results from the phase 3 True North study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Vermeire, S.(1)*;Abraham, B.(2);Bressler, B.(3);Reinisch, W.(4);Jain, A.(5);Memaj, A.(5);Akukwe, L.(5);Liu, W.J.(5);Osterman, M.(5);Canavan, J.B.(5);Sands, B.E.(6);
Created: Friday, 14 July 2023, 11:05 AM
P585: Efficacy of iDose dashboard forecast for individualising Infliximab therapy: an Indian experience
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Dave1, A. Dherai1, D. Desai*2, D. Mould3, T. Ashavaid1

Created: Friday, 22 February 2019, 9:41 AM
P585: Examining faecal incontinence and its impact on health-related quality of life in patients with Crohn’s perianal fistulas: results from a multi-country burden of illness study
Year: 2022
Source: ECCO'22
Authors: Karki, C.(1);Athavale, A.(2);Hantsbarger, G.(3);Lee, K.(4);Milicevic, S.(5);Perovic, M.(6);Raven, L.(7);Sajak-Szczerba, M.(8);Sharpe, E.(9);Tozer, P.(10);
Created: Friday, 11 February 2022, 3:56 PM
P585: IBD Reference and Biosimilar adalimumab CroSS over Study (iBaSS): a mixed methods clinical trial of patients transitioning between originator and biosimilar adalimumab. Qualitative findings from an interim analysis presenting the patient perspective.
Year: 2021
Source: ECCO'21 Virtual
Authors: Young, D.(1);Latter, S.(2);Harvey, J.(3);Addison, J.(4);Freudensprung, U.(5);Cummings, F.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P585: Impact of timing of thiopurine treatment on first intestinal resection in Crohn’s disease with poor prognostic factors: A nationwide population-based cohort study 2004–2015
Year: 2018
Source: ECCO '18 Vienna
Authors:

S.Y. Shin1*, J. Lee2, J.J. Park1, J.H. Cheon3, T.I. Kim3, H. Park1, W.H. Kim3, A.S. Shin2

Created: Thursday, 21 February 2019, 9:14 AM
P585: Infliximab in moderate to severe ulcerative colitis: comparison between scheduled treatment strategy and bridge strategy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sambuelli A.*1, Bellicoso M.2, Negreira S.2, Goncalves S.2, Huernos S.2, Chavero P.2, Tirado P.2, Cabanne A.3, Gil A.2

Created: Wednesday, 20 February 2019, 10:36 AM
P586 Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. GU1, K. Venkatesh2, A.J. Williams3, W. Ng3, C. Corte4, S. Ghaly2, W. Xuan5, S. Paramsothy6, S. Connor3

Created: Thursday, 30 January 2020, 10:12 AM